Rituximab: all 1,386 studies that test it
Page 11 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab EvaluationCompletedNCT01516567Phase 2
- Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin LymphomaCompletedNCT01482754Not applicable
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
- Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular LymphomaActive, not recruitingNCT01473628Phase 1/2
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesCompletedNCT01471067Phase 1
- Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01470456Phase 2
- Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)TerminatedNCT01458548Phase 2
- Study in Patients With Primary Breast Diffuse Large B-cell LymphomaCompletedNCT01448096Phase 2
- R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaTerminatedNCT01446900Phase 2
- Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)Active, not recruitingNCT01446133Phase 2
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)Status unknownNCT01439750Phase 1
- Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic LeukemiaStatus unknownNCT01429610Phase 2
- Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01429025Phase 1
- MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaWithdrawnNCT01415765Phase 1/2
- Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
- A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's LymphomaCompletedNCT01392716Phase 2
- A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT01388959Phase 2
- Intensified Rituimab Prephase Before FCR in Untreated B-CLLCompletedNCT01370772Phase 2
- Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic LeukemiaCompletedNCT01358253Phase 4
- Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal TransplantationCompletedNCT01350882Phase 3
- A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaCompletedNCT01345708Phase 2
- Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via CylexStatus unknownNCT01338103Not applicable
- Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell LymphomaCompletedNCT01334502Phase 1
- BRIEF Bendamustine and Rituximab In Elderly FollicularTerminatedNCT01313611Phase 2
- De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab InductionTerminatedNCT01312064Phase 4
- Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular LymphomaTerminatedNCT01307605Phase 2
- Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin LymphomaStatus unknownNCT01307592Phase 2
- Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by RituximabCompletedNCT01299857Phase 3
- A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaCompletedNCT01290549Phase 1
- Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin LymphomaCompletedNCT01290120Phase 2
- TREatment of degeNerative and Neoplastic Diseases With RituximabStatus unknownNCT01277172Phase 2/3
- Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During ChildhoodCompletedNCT01268033Phase 2/3
- Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid ArthritisCompletedNCT01244958Phase 3
- A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT01238692Phase 2
- Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)CompletedNCT01213095Phase 2
- A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's LymphomaCompletedNCT01209130Phase 1
- Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell LymphomaStatus unknownNCT01181999Phase 2
- Rituximab in Auto-Immune Hemolytic AnemiaCompletedNCT01181154Phase 3
- B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue SyndromeTerminatedNCT01156922Phase 2
- B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue SyndromeCompletedNCT01156909Phase 2
- Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal TransplantationCompletedNCT01136395Phase 2
- Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)CompletedNCT01135641Phase 2
- Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic AnemiaCompletedNCT01134432Phase 3
- Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First LineStatus unknownNCT01127841Phase 2
- Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) LymphomaCompletedNCT01124526Phase 4
- Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)CompletedNCT01118234Phase 3
- Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant PatientsTerminatedNCT01117662Phase 3
- A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)TerminatedNCT01117129Phase 4
- Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITPCompletedNCT01107951Phase 2
- Rituximab Maintenance After Autologous TransplantationTerminatedNCT01103388Phase 3
- RituxiMab INDuction in Renal TransplantationStatus unknownNCT01095172Phase 4
- Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)CompletedNCT01088724Phase 4
- A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)CompletedNCT01087151Phase 2
- Rituximab for Autoimmune RetinopathyCompletedNCT01086631Phase 1
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01085617
- Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell LymphomaCompletedNCT01078142Phase 1/2
- Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT01076556Phase 1
- Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal TransplantationStatus unknownNCT01066689Phase 3
- A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT01066598Phase 2
- Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01054781Phase 2
- Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaCompletedNCT01046006Phase 2
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Rituximab in Metastatic MelanomaTerminatedNCT01032122Phase 1
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With BendamustineCompletedNCT01022021Early Phase 1
- Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic TherapyCompletedNCT01021735Phase 4
- Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT01015248Phase 2
- Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's LymphomaStatus unknownNCT01009970Phase 2
- A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior TreatmentCompletedNCT01007292Phase 2
- Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host DiseaseWithdrawnNCT01001780Phase 2
- Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaCompletedNCT00992134Phase 2
- R-ABVD vs ABVD-RT in Early Stage Hodgkin's LymphomaTerminatedNCT00992030Phase 3
- Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell LymphomaCompletedNCT00987493Phase 1/2
- Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT00981838Phase 3
- R Retreatment in 1st Relapsed DLBCLStatus unknownNCT00980304Phase 2
- Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaStatus unknownNCT00974792Phase 2
- Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00971763Phase 2
- Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT00968331Phase 2
- High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell LymphomaCompletedNCT00965289Phase 2
- Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid ArthritisCompletedNCT00963703Not applicable
- Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.CompletedNCT00963534Phase 1/2
- Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent LymphomaTerminatedNCT00954005Phase 1/2
- S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00939328Phase 2
- A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and EfficacyCompletedNCT00936546Phase 2
- A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular LymphomaCompletedNCT00930514Phase 1
- Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)Status unknownNCT00927797Phase 2
- Mantel Cell Lymphoma Efficacy of Rituximab MaintenanceCompletedNCT00921414Phase 3
- The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00909077Phase 3
- Open Label Pilot Trial of Rituximab in Lupus Membranous NephritisWithdrawnNCT00908986Not applicable
- Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic PurpuraCompletedNCT00907751Phase 2
- GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaStatus unknownNCT00896519Phase 2
- GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaStatus unknownNCT00893477Phase 2
- Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic LeukemiaStatus unknownNCT00892827Phase 2
- Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to TreatmentWithdrawnNCT00881387Phase 2
- Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantCompletedNCT00880815Phase 1
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasActive, not recruitingNCT00877214Phase 3
- Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00868413Phase 1
- Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With RituximabStatus unknownNCT00863187Not applicable
- Rituximab for Pulmonary SarcoidosisCompletedNCT00855205Phase 2
- Drug Intervention in Chronic Fatigue SyndromeCompletedNCT00848692Phase 2/3
- Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT00848328Phase 2